The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

AstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...

The drug candidate improved progression-free survival in patients, it said.

In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

AstraZeneca has opened a plant to produce biogas from organic waste that will ensure by the end of this year all of its ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

Goldman Sachs analysts added AstraZeneca (AZN) to the firm’s European Conviction List as part of its monthly update. With 28 Phase-3 readouts ...

This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients ...

Alex Reid was wrongly advised on early vaccination due to a clinical mistake 17 years earlier. The firm said the decision was taken because of a decline in demand for the vaccine.